Supplementary material for Kang SY, et al. Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome? Acta Oncologica, 2015;54:1231–4.

Supplementary Table I. Comparison of patient characteristics between group A (<28 days) and B (≥28 days).

Characteristics	No. of patients	Group A (%)	Group B (%)	p-Value
Gender				
Male	286	233 (70.0)	53 (68.8)	0.891
Female	124	100 (30.0)	24 (31.2)	
Age (25–76 ^a)				
≤ 56 ^b	217	182 (54.7)	35 (45.5)	0.164
> 56	193	151 (45.3)	42 (54.5)	
Operation type				
Subtotal	267	223 (67.0)	44 (57.1)	0.112
Total	143	110 (33.0)	33 (42.9)	
Site				
Lower	175	145 (43.5)	30 (39.0)	0.758
Middle	126	101 (30.3)	25 (32.5)	
Upper	56	44 (13.2)	12 (15.6)	
Diffuse	19	14 (4.2)	5 (6.5)	
Others ^c	34	29 (8.7)	5 (6.5)	
Tumor size (cm)				
≤ 5.5 ^b	226	183 (55.0)	43 (55.8)	0.90
> 5.5	184	150 (45.0)	34 (44.2)	
Borrmann type				
I	16	14 (4.2)	2 (2.6)	0.909
II	57	45 (13.5)	12 (15.6)	
III	265	216 (64.9)	49 (63.6)	
IV	72	58 (17.4)	14 (18.2)	
Stage ^d				
IIA	60	45 (13.5)	15 (19.5)	0.117
IIB	84	70 (21.0)	14 (18.2)	
IIIA	66	58 (17.4)	8 (10.4)	
IIIB	86	74 (22.2)	12 (15.6)	
IIIC	114	86 (25.8)	28 (36.4)	
WHO classification				
Well	17	11 (3.3)	6 (7.8)	0.158
Moderate	96	80 (24.0)	16 (20.8)	
Poor	208	164 (49.2)	44 (57.1)	
Signet ring cell	76	67 (20.1)	9 (11.7)	
Others ^e	13	11 (3.3)	2 (2.6)	
Postoperative complications				
Absent	383	325 (97.6)	58 (75.3)	<0.0001
Present	27	8 (2.4)	19 (24.7)	

WHO, World Health Organization.

^aRange; ^bmedian; ^cincluding overlapped or multifocal type; ^dAmerican Joint Committee on Cancer 7th edition; ^eincluding undifferentiated carcinoma or mixed types.

Supplementary Table II. Univariate analysis of overall survival according to various prognostic factors.

Prognostic factors	No. of patients	10-year OS (%)	HR (95% CI)	p-Value
Gender				
Male	286	51.6	1	0.127
Female	124	59.6	0.78 (0.57–1.07)	
Age				
< 56 ^a	217	62.6	1	< 0.0001
≥ 56	193	44.5	1.84 (1.39–2.44)	
Operation type				
Subtotal	267	60.5	1	0.002
Total	143	41.9	1.55 (1.17–2.06)	
Site				
Lower	175	54.7	1	0.079
Middle	126	56.9	1.02 (0.73–1.42)	
Upper	56	58.9	0.82 (0.52–1.31)	
Diffuse	19	31.6	2.00 (1.11–3.59)	
Others ^b	34	43.5	1.32 (0.81–2.16)	
Tumor size (cm)				
≤ 5.5 ^a	226	64.1	1	< 0.0001
> 5.5	184	41.7	1.97 (1.49–2.61)	
Borrmann type				
I or II	73	71.2	1	< 0.0001
III	265	56.1	1.61 (1.04–2.49)	
IV	72	29.0	3.35 (2.06–5.45)	
Stage ^c				
IIA	60	85.0	1	< 0.0001
IIB	84	73.7	2.04 (0.99–4.24)	
IIIA	66	68.0	2.67 (1.29–5.53)	
IIIB	86	42.8	4.83 (2.45–9.52)	
IIIC	114	23.5	8.75 (4.54–16.88)	
WHO classification				
Well or moderate	113	60.9	1	0.506
Poor	208	52.3	1.21 (0.87–1.70)	
Signet ring cell	76	48.5	1.34 (0.88–2.03)	
Others ^d	13	53.8	1.43 (0.65–3.15)	
Timing of chemotherapy 1				
Early (< 21 days)	178	57.3	1	0.409
Late (≥ 21 days)	232	51.4	1.13 (0.85–1.49)	
Timing of chemotherapy 2				
Group A (< 28 days)	333	57.5	1	0.003
Group B (≥ 28 days)	77	38.8	1.63 (1.17–2.26)	
Postoperative complications				
Absent	383	53.4	1	0.298
Present	27	63.0	0.72 (0.38–1.35)	

CI, confidence interval; HR, hazard ratio; OS, overall survival; WHO, World Health Organization.

^aMedian; ^bincluding overlapped or multifocal type; ^cAmerican Joint Committee on Cancer 7th edition;^dincluding undifferentiated carcinoma or mixed types.